Please use this identifier to cite or link to this item:
Title: Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
Authors: Vavlukis, Marija 
Kotlar, Irina
Taravari, Hajber
Poposka, Lidija 
Kedev, Sasko 
Keywords: heparin-induced thrombocytopenia, rivaroxaban, pulmonary thromboembolism
Issue Date: Jul-2017
Journal: Anatolian journal of cardiology
Abstract: Heparin-induced thrombocytopenia (HIT) is an adverse effect of heparin therapy (1). There are two types of HIT: non-immunomediated (HIT-I) and immunomediated (HIT-II) disorders. HIT-II is characterized by the formation of IgG antibodies against the heparin-PLT factor 4 complex (PF4) (1, 2). Bounded with heparin, this factor creates a neoantigen and stimulates the production of antibodies (2). Activated PLTs, along with the heparin/PF4 antibody complex attached to their surface, undergo aggregation and premature removal from the circulation, leading to thrombocytopenia and additionally to a procoagulant state with high potential for thrombus formation and thromboembolic events (3). The incidence of HIT-II is 0.1%–1% in low-molecular-weight heparins (LMWH) and 3%–5% in un-fractionated heparin (UHF)- treated patients (3). In HIT-II, the PLT count drop can be seen 3–4 days after exposure in patients with pre-existing heparin- PF4 antibodies from a previous exposure to heparin, whereas in those exposed for the first time, the PLT count drops 5–10 days after heparin administration (3). It has been confirmed that new oral anticoagulants (NOACs) offer advantages regarding this side effect (4), and this case report aims to share our first positive experience in relation to the previously mentioned.
DOI: 10.14744/AnatolJCardiol.2017.7805
Appears in Collections:Faculty of Medicine: Journal Articles

Show full item record

Page view(s)

checked on Apr 5, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.